SlideShare a Scribd company logo
1 of 11
S.Prasanth Kumar, Bioinformatician Pharmacogenomics & Drug Design Fragment Based Drug Design (FBDD) S.Prasanth Kumar, Bioinformatician S.Prasanth Kumar   Dept. of Bioinformatics  Applied Botany Centre (ABC)  Gujarat University, Ahmedabad, INDIA www.facebook.com/Prasanth Sivakumar FOLLOW ME ON  ACCESS MY RESOURCES IN SLIDESHARE prasanthperceptron CONTACT ME [email_address]
Definition By definition,  de novo  means “ from the new ” and involves the design of complex new molecules from smaller constituent parts The typical fragment-based project begins with an “ efficient” binder , which may not be a particularly tight binder.
Why FBDD ? High-throughput screening   (HTS)  of pre-existing compounds in a variety of pharmacological assays is still the  most widely used approach to hit discovery .  Half of all HTS screens  fail to deliver appropriate chemical starting points  for new discovery programmes.  Reasons: the non drug-like compounds present in many chemical archives assembled by random combinatorial chemistry approaches These compounds  cannot be optimized  into development candidates It is usually more efficient to start discovery from  creating new target-focused libraries of ‘lead-like’ compounds which can be more readily optimized
FBDD Approaches: Fragment Elaboration Lead optimisation by fragment elaboration and/or recombination Fragment library screening
FBDD Approaches: Fragment Fusion Fragment library screening Lead optimization by fragment combination and scaffold hopping
FBDD-the process Rule-of-3 compliant Fragment library Optimised for sensitivity Biological Assay High-concentration screening Hit Structure-guided hit elaboration Traditional lead optimisation
From Fragments to Drugs Lead compound derived  based on fragment hits  Bcl-xL with natural peptide bound By NMR Structure of clinical candidate ABT-737
Fragment-based design series Overlay of virtual screening hit and lead compound virtual screening hit Intermediate compound similar to the virtual screening hit    that confirmed the predicted binding mode  Lead compound with 0.021  μ M affinity
FBDD-the process The generation of a suitable Fragment Library fragments usually comply with the ‘ Rule of 3’ (Ro3) fragments should have MW > 300, LogP > three, and Hydrogen bond donors & acceptors >3 Ligand efficiency (LE)  can be regarded as the average binding energy per atom or per mass unit of the structure. Fragments having  high LEs  can be selected at  both at the start of and during the FBDD process Fragment Screening Techniques  : XRD & NMR
FBDD-the process Fragment Elaboration If more than one fragment is found to bind in an active site, these fragments may be chemically linked to form a larger moiety One apparent  disadvantage  of the FBDD approach – when small, generic fragments are used as design ‘seeds’ –  lies in the uniformity of the process. Two laboratories using the same fragment in identical modes might reasonably be expected to ‘discover’ similar chemical series. SBDD-the future of FBDD
Thank You For Your Attention !!!

More Related Content

What's hot

In Silico methods for ADMET prediction of new molecules
 In Silico methods for ADMET prediction of new molecules In Silico methods for ADMET prediction of new molecules
In Silico methods for ADMET prediction of new moleculesMadhuraDatar
 
PREDICTION AND ANALYSIS OF ADMET PROPERTIES OF NEW.pptx
PREDICTION AND ANALYSIS OF ADMET PROPERTIES OF NEW.pptxPREDICTION AND ANALYSIS OF ADMET PROPERTIES OF NEW.pptx
PREDICTION AND ANALYSIS OF ADMET PROPERTIES OF NEW.pptxMO.SHAHANAWAZ
 
De novo drug design
De novo drug designDe novo drug design
De novo drug designmojdeh y
 
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENTPHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENTShikha Popali
 
Molecular and Quantum Mechanics in drug design
Molecular and Quantum Mechanics in drug designMolecular and Quantum Mechanics in drug design
Molecular and Quantum Mechanics in drug designAjay Kumar
 
de novo drug design
de novo drug designde novo drug design
de novo drug designmojdeh y
 
Molecular docking by harendra ...power point presentation
Molecular docking by harendra ...power point presentationMolecular docking by harendra ...power point presentation
Molecular docking by harendra ...power point presentationHarendra Bisht
 
Free wilson analysis qsar
Free wilson analysis qsarFree wilson analysis qsar
Free wilson analysis qsarRahul B S
 
Pharmacophore mapping and virtual screening
Pharmacophore mapping and virtual screeningPharmacophore mapping and virtual screening
Pharmacophore mapping and virtual screeningSanchit Dhankhar
 
Quantitative structure activity relationships
Quantitative structure  activity relationshipsQuantitative structure  activity relationships
Quantitative structure activity relationshipsAmiya ghosh
 
(Kartik Tiwari) Denovo Drug Design.pptx
(Kartik Tiwari) Denovo Drug Design.pptx(Kartik Tiwari) Denovo Drug Design.pptx
(Kartik Tiwari) Denovo Drug Design.pptxKartik Tiwari
 
Virtual screening strategies and applications
Virtual screening strategies and applicationsVirtual screening strategies and applications
Virtual screening strategies and applicationsAshishkumar3249
 
DENOVO DRUG DESIGN AS PER PCI SYLLABUS
DENOVO DRUG DESIGN AS PER PCI SYLLABUSDENOVO DRUG DESIGN AS PER PCI SYLLABUS
DENOVO DRUG DESIGN AS PER PCI SYLLABUSShikha Popali
 

What's hot (20)

In Silico methods for ADMET prediction of new molecules
 In Silico methods for ADMET prediction of new molecules In Silico methods for ADMET prediction of new molecules
In Silico methods for ADMET prediction of new molecules
 
PREDICTION AND ANALYSIS OF ADMET PROPERTIES OF NEW.pptx
PREDICTION AND ANALYSIS OF ADMET PROPERTIES OF NEW.pptxPREDICTION AND ANALYSIS OF ADMET PROPERTIES OF NEW.pptx
PREDICTION AND ANALYSIS OF ADMET PROPERTIES OF NEW.pptx
 
De novo drug design
De novo drug designDe novo drug design
De novo drug design
 
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENTPHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
PHARMACOHORE MAPPING AND VIRTUAL SCRRENING FOR RESEARCH DEPARTMENT
 
Pharmacophore mapping joon
Pharmacophore mapping joonPharmacophore mapping joon
Pharmacophore mapping joon
 
Molecular and Quantum Mechanics in drug design
Molecular and Quantum Mechanics in drug designMolecular and Quantum Mechanics in drug design
Molecular and Quantum Mechanics in drug design
 
de novo drug design
de novo drug designde novo drug design
de novo drug design
 
Molecular docking by harendra ...power point presentation
Molecular docking by harendra ...power point presentationMolecular docking by harendra ...power point presentation
Molecular docking by harendra ...power point presentation
 
Denovo Drug Design
Denovo Drug DesignDenovo Drug Design
Denovo Drug Design
 
Free wilson analysis qsar
Free wilson analysis qsarFree wilson analysis qsar
Free wilson analysis qsar
 
Pharmacophore mapping and virtual screening
Pharmacophore mapping and virtual screeningPharmacophore mapping and virtual screening
Pharmacophore mapping and virtual screening
 
3D QSAR
3D QSAR3D QSAR
3D QSAR
 
2D - QSAR
2D - QSAR2D - QSAR
2D - QSAR
 
Presentation on concept of pharmacophore mapping and pharmacophore based scre...
Presentation on concept of pharmacophore mapping and pharmacophore based scre...Presentation on concept of pharmacophore mapping and pharmacophore based scre...
Presentation on concept of pharmacophore mapping and pharmacophore based scre...
 
Quantitative structure activity relationships
Quantitative structure  activity relationshipsQuantitative structure  activity relationships
Quantitative structure activity relationships
 
Conformational analysis – Alignment of molecules in 3D QSAR
Conformational analysis  – Alignment of molecules in 3D QSARConformational analysis  – Alignment of molecules in 3D QSAR
Conformational analysis – Alignment of molecules in 3D QSAR
 
(Kartik Tiwari) Denovo Drug Design.pptx
(Kartik Tiwari) Denovo Drug Design.pptx(Kartik Tiwari) Denovo Drug Design.pptx
(Kartik Tiwari) Denovo Drug Design.pptx
 
Stereochemical aspects
Stereochemical aspectsStereochemical aspects
Stereochemical aspects
 
Virtual screening strategies and applications
Virtual screening strategies and applicationsVirtual screening strategies and applications
Virtual screening strategies and applications
 
DENOVO DRUG DESIGN AS PER PCI SYLLABUS
DENOVO DRUG DESIGN AS PER PCI SYLLABUSDENOVO DRUG DESIGN AS PER PCI SYLLABUS
DENOVO DRUG DESIGN AS PER PCI SYLLABUS
 

Similar to Fbdd

FRAGMENT-BASED DRUG DISCOVERY.pptx
FRAGMENT-BASED DRUG DISCOVERY.pptxFRAGMENT-BASED DRUG DISCOVERY.pptx
FRAGMENT-BASED DRUG DISCOVERY.pptxMO.SHAHANAWAZ
 
Molecular Modeling and virtual screening techniques
Molecular Modeling and virtual screening techniquesMolecular Modeling and virtual screening techniques
Molecular Modeling and virtual screening techniquesTheabhi.in
 
Significance of computational tools in drug discovery
Significance of computational tools in drug discoverySignificance of computational tools in drug discovery
Significance of computational tools in drug discoveryDrMopuriDeepaReddy
 
Drug design based on bioinformatic tools
Drug design based on bioinformatic toolsDrug design based on bioinformatic tools
Drug design based on bioinformatic toolsSujeethKrishnan
 
Pharmacophore mapping in Drug Development
Pharmacophore mapping in Drug DevelopmentPharmacophore mapping in Drug Development
Pharmacophore mapping in Drug DevelopmentMbachu Chinedu
 
Computer aided drug design Fragment Based Drug Design/ Medicinal Chemistry, I...
Computer aided drug design Fragment Based Drug Design/ Medicinal Chemistry, I...Computer aided drug design Fragment Based Drug Design/ Medicinal Chemistry, I...
Computer aided drug design Fragment Based Drug Design/ Medicinal Chemistry, I...SourajyotiGoswami
 
“Docking Studies and Drug Design”
“Docking  Studies and Drug Design”“Docking  Studies and Drug Design”
“Docking Studies and Drug Design”Naresh Juttu
 
Cadd and molecular modeling for M.Pharm
Cadd and molecular modeling for M.PharmCadd and molecular modeling for M.Pharm
Cadd and molecular modeling for M.PharmShikha Popali
 
Determining stable ligand orientation
Determining stable ligand orientationDetermining stable ligand orientation
Determining stable ligand orientationijaia
 
SAR BY NMR (Structure Activity Relationship by Using NMR)
SAR BY NMR (Structure Activity Relationship by Using NMR)SAR BY NMR (Structure Activity Relationship by Using NMR)
SAR BY NMR (Structure Activity Relationship by Using NMR)SAKEEL AHMED
 
Structure based drug designing
Structure based drug designingStructure based drug designing
Structure based drug designingSeenam Iftikhar
 
Stable Drug Designing by Minimizing Drug Protein Interaction Energy Using PSO
Stable Drug Designing by Minimizing Drug Protein Interaction Energy Using PSO Stable Drug Designing by Minimizing Drug Protein Interaction Energy Using PSO
Stable Drug Designing by Minimizing Drug Protein Interaction Energy Using PSO csandit
 
Computer aided drug designing
Computer aided drug designing Computer aided drug designing
Computer aided drug designing Ayesha Aftab
 
COMPUTER ASSISTED DRUG DISCOVERY
COMPUTER ASSISTED DRUG DISCOVERYCOMPUTER ASSISTED DRUG DISCOVERY
COMPUTER ASSISTED DRUG DISCOVERYAmrutha Lakshmi
 
Virtual screening techniques
Virtual screening techniquesVirtual screening techniques
Virtual screening techniquesROHIT PAL
 

Similar to Fbdd (20)

De novo drug design
De novo drug designDe novo drug design
De novo drug design
 
FRAGMENT-BASED DRUG DISCOVERY.pptx
FRAGMENT-BASED DRUG DISCOVERY.pptxFRAGMENT-BASED DRUG DISCOVERY.pptx
FRAGMENT-BASED DRUG DISCOVERY.pptx
 
Molecular Modeling and virtual screening techniques
Molecular Modeling and virtual screening techniquesMolecular Modeling and virtual screening techniques
Molecular Modeling and virtual screening techniques
 
Significance of computational tools in drug discovery
Significance of computational tools in drug discoverySignificance of computational tools in drug discovery
Significance of computational tools in drug discovery
 
Drug design based on bioinformatic tools
Drug design based on bioinformatic toolsDrug design based on bioinformatic tools
Drug design based on bioinformatic tools
 
Cadd
CaddCadd
Cadd
 
Pharmacophore mapping in Drug Development
Pharmacophore mapping in Drug DevelopmentPharmacophore mapping in Drug Development
Pharmacophore mapping in Drug Development
 
SBDD.pptx
SBDD.pptxSBDD.pptx
SBDD.pptx
 
Computer aided drug design Fragment Based Drug Design/ Medicinal Chemistry, I...
Computer aided drug design Fragment Based Drug Design/ Medicinal Chemistry, I...Computer aided drug design Fragment Based Drug Design/ Medicinal Chemistry, I...
Computer aided drug design Fragment Based Drug Design/ Medicinal Chemistry, I...
 
“Docking Studies and Drug Design”
“Docking  Studies and Drug Design”“Docking  Studies and Drug Design”
“Docking Studies and Drug Design”
 
Cadd and molecular modeling for M.Pharm
Cadd and molecular modeling for M.PharmCadd and molecular modeling for M.Pharm
Cadd and molecular modeling for M.Pharm
 
Determining stable ligand orientation
Determining stable ligand orientationDetermining stable ligand orientation
Determining stable ligand orientation
 
SAR BY NMR (Structure Activity Relationship by Using NMR)
SAR BY NMR (Structure Activity Relationship by Using NMR)SAR BY NMR (Structure Activity Relationship by Using NMR)
SAR BY NMR (Structure Activity Relationship by Using NMR)
 
Structure based drug designing
Structure based drug designingStructure based drug designing
Structure based drug designing
 
Drug design and toxicology
Drug design and toxicologyDrug design and toxicology
Drug design and toxicology
 
Stable Drug Designing by Minimizing Drug Protein Interaction Energy Using PSO
Stable Drug Designing by Minimizing Drug Protein Interaction Energy Using PSO Stable Drug Designing by Minimizing Drug Protein Interaction Energy Using PSO
Stable Drug Designing by Minimizing Drug Protein Interaction Energy Using PSO
 
Computer Aided Drug Design
Computer Aided Drug DesignComputer Aided Drug Design
Computer Aided Drug Design
 
Computer aided drug designing
Computer aided drug designing Computer aided drug designing
Computer aided drug designing
 
COMPUTER ASSISTED DRUG DISCOVERY
COMPUTER ASSISTED DRUG DISCOVERYCOMPUTER ASSISTED DRUG DISCOVERY
COMPUTER ASSISTED DRUG DISCOVERY
 
Virtual screening techniques
Virtual screening techniquesVirtual screening techniques
Virtual screening techniques
 

More from Prasanthperceptron

More from Prasanthperceptron (20)

Prasanth Chikungunya Viral nsP4
Prasanth Chikungunya Viral nsP4 Prasanth Chikungunya Viral nsP4
Prasanth Chikungunya Viral nsP4
 
Maize poster
Maize posterMaize poster
Maize poster
 
Structure determination
Structure determinationStructure determination
Structure determination
 
S. prasanth kumar young scientist awarded presentation
S. prasanth kumar young scientist awarded presentationS. prasanth kumar young scientist awarded presentation
S. prasanth kumar young scientist awarded presentation
 
Soft copy of abstracts
Soft copy of abstractsSoft copy of abstracts
Soft copy of abstracts
 
Protein stability manual
Protein stability manualProtein stability manual
Protein stability manual
 
ORVIL Manual
ORVIL ManualORVIL Manual
ORVIL Manual
 
2 d qsar model of dihydrofolate reductase (dhfr) inhibitors with activity in ...
2 d qsar model of dihydrofolate reductase (dhfr) inhibitors with activity in ...2 d qsar model of dihydrofolate reductase (dhfr) inhibitors with activity in ...
2 d qsar model of dihydrofolate reductase (dhfr) inhibitors with activity in ...
 
Epitope prediction and its algorithms
Epitope prediction and its algorithmsEpitope prediction and its algorithms
Epitope prediction and its algorithms
 
Gene order
Gene orderGene order
Gene order
 
Vls
VlsVls
Vls
 
The mechanism of protein folding
The mechanism of protein foldingThe mechanism of protein folding
The mechanism of protein folding
 
Sequence alignments complete coverage
Sequence alignments complete coverageSequence alignments complete coverage
Sequence alignments complete coverage
 
Sage technology
Sage technologySage technology
Sage technology
 
Proteome databases
Proteome databasesProteome databases
Proteome databases
 
Protein protein interactions
Protein protein interactionsProtein protein interactions
Protein protein interactions
 
Protein dna interaction practical
Protein dna interaction  practicalProtein dna interaction  practical
Protein dna interaction practical
 
Protein dna interaction
Protein dna interactionProtein dna interaction
Protein dna interaction
 
Primary databases ncbi
Primary databases ncbiPrimary databases ncbi
Primary databases ncbi
 
Pharmacophore identification
Pharmacophore identificationPharmacophore identification
Pharmacophore identification
 

Fbdd

  • 1. S.Prasanth Kumar, Bioinformatician Pharmacogenomics & Drug Design Fragment Based Drug Design (FBDD) S.Prasanth Kumar, Bioinformatician S.Prasanth Kumar Dept. of Bioinformatics Applied Botany Centre (ABC) Gujarat University, Ahmedabad, INDIA www.facebook.com/Prasanth Sivakumar FOLLOW ME ON ACCESS MY RESOURCES IN SLIDESHARE prasanthperceptron CONTACT ME [email_address]
  • 2. Definition By definition, de novo means “ from the new ” and involves the design of complex new molecules from smaller constituent parts The typical fragment-based project begins with an “ efficient” binder , which may not be a particularly tight binder.
  • 3. Why FBDD ? High-throughput screening (HTS) of pre-existing compounds in a variety of pharmacological assays is still the most widely used approach to hit discovery . Half of all HTS screens fail to deliver appropriate chemical starting points for new discovery programmes. Reasons: the non drug-like compounds present in many chemical archives assembled by random combinatorial chemistry approaches These compounds cannot be optimized into development candidates It is usually more efficient to start discovery from creating new target-focused libraries of ‘lead-like’ compounds which can be more readily optimized
  • 4. FBDD Approaches: Fragment Elaboration Lead optimisation by fragment elaboration and/or recombination Fragment library screening
  • 5. FBDD Approaches: Fragment Fusion Fragment library screening Lead optimization by fragment combination and scaffold hopping
  • 6. FBDD-the process Rule-of-3 compliant Fragment library Optimised for sensitivity Biological Assay High-concentration screening Hit Structure-guided hit elaboration Traditional lead optimisation
  • 7. From Fragments to Drugs Lead compound derived based on fragment hits Bcl-xL with natural peptide bound By NMR Structure of clinical candidate ABT-737
  • 8. Fragment-based design series Overlay of virtual screening hit and lead compound virtual screening hit Intermediate compound similar to the virtual screening hit that confirmed the predicted binding mode Lead compound with 0.021 μ M affinity
  • 9. FBDD-the process The generation of a suitable Fragment Library fragments usually comply with the ‘ Rule of 3’ (Ro3) fragments should have MW > 300, LogP > three, and Hydrogen bond donors & acceptors >3 Ligand efficiency (LE) can be regarded as the average binding energy per atom or per mass unit of the structure. Fragments having high LEs can be selected at both at the start of and during the FBDD process Fragment Screening Techniques : XRD & NMR
  • 10. FBDD-the process Fragment Elaboration If more than one fragment is found to bind in an active site, these fragments may be chemically linked to form a larger moiety One apparent disadvantage of the FBDD approach – when small, generic fragments are used as design ‘seeds’ – lies in the uniformity of the process. Two laboratories using the same fragment in identical modes might reasonably be expected to ‘discover’ similar chemical series. SBDD-the future of FBDD
  • 11. Thank You For Your Attention !!!